Ola E Dahl

Summary

Affiliation: University of Oslo
Country: Norway

Publications

  1. ncbi request reprint Current controversies in deep vein thrombosis prophylaxis after orthopaedic surgery
    Ola E Dahl
    Department of Orthopaedics and Research Forum, Ullevaal University Hospital, Oslo, Norway
    Curr Opin Pulm Med 8:394-7. 2002
  2. doi request reprint Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
    Ajay K Kakkar
    Barts and the London School of Medicine and Dentistry, London, UK
    Lancet 372:31-9. 2008
  3. ncbi request reprint Fatal vascular outcomes following major orthopedic surgery
    Ola E Dahl
    Thrombosis Research Institute, London, UK
    Thromb Haemost 93:860-6. 2005
  4. ncbi request reprint Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
    Bengt I Eriksson
    Department of Orthopaedic Surgery, Sahlgrenska University Hospital Ostra, Gothenburg, Sweden
    Lancet 370:949-56. 2007
  5. ncbi request reprint Orthopaedic surgery as a model for drug development in thrombosis
    Ola E Dahl
    Department of Orthopaedics, Buskerud Central Hospital, Section for Joint Implants and Medical Science, Drammen, Norway
    Drugs 64:17-25. 2004
  6. pmc What treatment for periprosthetic shoulder infection? Results from a multicentre retrospective series
    Carlo Luca Romano
    Dipartimento di Chirurgia Ricostruttiva e delle InfezioniOsteo articolari, Istituto Ortopedico I R C C S Galeazzi, Via Riccardo Galeazzi, 4, Milano 20161, Italy
    Int Orthop 36:1011-7. 2012
  7. pmc Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected]
    Ola E Dahl
    Department of Orthopaedics, Elverum Central Hospital, Kirkevn 7, 2418 Elverum, Norway
    Int Orthop 36:741-8. 2012
  8. pmc New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders
    Ola E Dahl
    Department of Orthopaedics, Innlandet Hospital Trust, Elverum Central Hospital, Elverum, Norway
    Vasc Health Risk Manag 8:45-57. 2012
  9. ncbi request reprint Major joint replacement. A model for antithrombotic drug development: from proof-of-concept to clinical use
    O E Dahl
    International Surgical Thrombosis Forum, Thrombosis Research Institute, London, UK
    Int Angiol 27:60-7. 2008
  10. doi request reprint Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen
    Ola E Dahl
    Department of Orthopaedics, Elverum Central Hospital, Norway, and Thrombosis Research Institute, London, United Kingdom
    Clin Appl Thromb Hemost 15:17S-24S. 2009

Collaborators

Detail Information

Publications36

  1. ncbi request reprint Current controversies in deep vein thrombosis prophylaxis after orthopaedic surgery
    Ola E Dahl
    Department of Orthopaedics and Research Forum, Ullevaal University Hospital, Oslo, Norway
    Curr Opin Pulm Med 8:394-7. 2002
    ..Clinical studies on vascular endpoints are warranted to achieve relevant basic data for health economic analyses, which also lack scientific standardized procedures. An intercontinental close cooperation is needed to solve these issues...
  2. doi request reprint Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
    Ajay K Kakkar
    Barts and the London School of Medicine and Dentistry, London, UK
    Lancet 372:31-9. 2008
    ..Our aim was to compare the use of rivaroxaban for extended thromboprophylaxis with short-term thromboprophylaxis with enoxaparin...
  3. ncbi request reprint Fatal vascular outcomes following major orthopedic surgery
    Ola E Dahl
    Thrombosis Research Institute, London, UK
    Thromb Haemost 93:860-6. 2005
    ..In conclusion, although prophylaxis results in a reduction in overall mortality and fatal pulmonary embolism, vascular events continue to be a common cause of mortality...
  4. ncbi request reprint Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
    Bengt I Eriksson
    Department of Orthopaedic Surgery, Sahlgrenska University Hospital Ostra, Gothenburg, Sweden
    Lancet 370:949-56. 2007
    ..After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis...
  5. ncbi request reprint Orthopaedic surgery as a model for drug development in thrombosis
    Ola E Dahl
    Department of Orthopaedics, Buskerud Central Hospital, Section for Joint Implants and Medical Science, Drammen, Norway
    Drugs 64:17-25. 2004
    ..In addition, geographical differences in treatment regimens regarding the choice of agent, timing of initiation and duration of thromboprophylaxis, and how these influence the incidence of venous thromboembolism, will be discussed...
  6. pmc What treatment for periprosthetic shoulder infection? Results from a multicentre retrospective series
    Carlo Luca Romano
    Dipartimento di Chirurgia Ricostruttiva e delle InfezioniOsteo articolari, Istituto Ortopedico I R C C S Galeazzi, Via Riccardo Galeazzi, 4, Milano 20161, Italy
    Int Orthop 36:1011-7. 2012
    ..The aim of this multi-institutional study was to review a continuous retrospectiveseries of patients treated in four European centres and to assess the respective eradication rate of various treatment approaches...
  7. pmc Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected]
    Ola E Dahl
    Department of Orthopaedics, Elverum Central Hospital, Kirkevn 7, 2418 Elverum, Norway
    Int Orthop 36:741-8. 2012
    ..Our objective was to understand the efficacy and bleeding data for the lower dose in this subpopulation...
  8. pmc New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders
    Ola E Dahl
    Department of Orthopaedics, Innlandet Hospital Trust, Elverum Central Hospital, Elverum, Norway
    Vasc Health Risk Manag 8:45-57. 2012
    ....
  9. ncbi request reprint Major joint replacement. A model for antithrombotic drug development: from proof-of-concept to clinical use
    O E Dahl
    International Surgical Thrombosis Forum, Thrombosis Research Institute, London, UK
    Int Angiol 27:60-7. 2008
    ..In this paper, the International Surgical Thrombosis Forum proposes a strategy for the clinical investigation of new pharmacological agents for the prophylaxis of postoperative thrombotic events...
  10. doi request reprint Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen
    Ola E Dahl
    Department of Orthopaedics, Elverum Central Hospital, Norway, and Thrombosis Research Institute, London, United Kingdom
    Clin Appl Thromb Hemost 15:17S-24S. 2009
    ..These doses were selected to ensure that the risk of bleeding did not exceed that of enoxaparin. This review discusses the rationale for selection of these dose regimens based on results from phase II trials...
  11. ncbi request reprint Divergent regional opinions on thromboembolic complications and prophylaxis among surgeons
    O E Dahl
    Thrombosis Research Institute, London, UK
    J Thromb Haemost 2:1899-900. 2004
  12. ncbi request reprint Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty
    Ola E Dahl
    International Surgical Thrombosis Forum, Thrombosis Research Institute, London, UK
    Pathophysiol Haemost Thromb 35:428-34. 2006
    ..4-12 h) when compared with preoperative (12 h) administration of enoxaparin. Transfusion rates were significantly lower with administration of melagatran/ximelagatran compared with enoxaparin...
  13. ncbi request reprint Risk of clinical pulmonary embolism after joint surgery in patients receiving low-molecular-weight heparin prophylaxis in hospital: a 10-year prospective register of 3,954 patients
    Ola E Dahl
    Department of Orthopaedics and Research Forum, Ulleval University Hospital, Oslo, Norway
    Acta Orthop Scand 74:299-304. 2003
    ..The differences in PE incidence and the time when it developed in NHF versus THR and TKR patients suggest that these patients should be considered separately when determining the optimal thromboprophylactic regimen...
  14. ncbi request reprint Investment in prolonged thromboprophylaxis with dalteparin improves clinical outcomes after hip replacement
    O E Dahl
    Department of Orthopaedics, Research Forum, Ullevaal University Hospital, Oslo, Norway
    J Thromb Haemost 1:896-906. 2003
    ..We consider that investment in prolonged thromboprophylaxis with dalteparin is justified for the improvement in clinical outcomes produced...
  15. ncbi request reprint Continuing out-of-hospital prophylaxis following major orthopaedic surgery: what now?
    O E Dahl
    Department of Orthopaedics, Ullevaal University Hospital, Oslo, Norway
    Haemostasis 30:101-5; discussion 82-3. 2000
    ....
  16. ncbi request reprint Preoperative versus postoperative initiation of dalteparin thromboprophylaxis in THA
    Pål O Borgen
    Department of Orthopaedics, Martina Hansens Hospital, Oslo, Norway
    Hip Int 20:301-7. 2010
    ..Few thromboembolic events occurred, and these were equally distributed...
  17. doi request reprint Biochemical lung, liver and kidney markers and early death among elderly following hip fracture
    Ove Talsnes
    Department of Orthopaedics, Sykehuset Innlandet Hospital Trust, Elverum, Norway
    Arch Orthop Trauma Surg 132:1753-8. 2012
    ..This study was conducted to assess biological markers on perioperative organ dysfunction and its association with early mortality within 3 months after surgery...
  18. ncbi request reprint Ximelagatran as a new oral anticoagulant for thrombosis
    Ola E Dahl
    Thrombosis Research Institute, London, United Kingdom
    Semin Vasc Med 5:223-5. 2005
  19. ncbi request reprint Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery
    D J Quinlan
    Department of Radiology, King s College Hospital, London, UK
    J Thromb Haemost 5:1438-43. 2007
    ..Venography is commonly used to compare the efficacy of different thromboprophylaxis strategies for preventing deep vein thrombosis (DVT) in patients undergoing total hip replacement (THR) or total knee replacement (TKR)...
  20. ncbi request reprint Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin
    H Arnesen
    Center for Clinical Research, Department of Orthopedic Surgery, Ulleval University Hospital, Oslo, Norway
    J Thromb Haemost 1:971-5. 2003
    ..0 when compared with patients in the lowest quartile (<1625 ng mL-1). It is concluded that a substantial hypercoagulability is sustained until day 35 after HRS, significantly reduced with prolonged administration of dalteparin...
  21. doi request reprint Thrombin split products (prothrombin fragment 1 + 2) in urine in patients with suspected deep vein thrombosis admitted for radiological verification
    Fredrik Wexels
    Department of Radiology, Vestre Viken Hospital Trust, Drammen, Norway
    Thromb Res 131:560-3. 2013
    ..We wanted to assess if F1 + 2 was released in urine (uF1 + 2) in patients with procoagulant disorders, and if higher levels were found in patients with radiological verified deep vein thrombosis (DVT)...
  22. pmc Perioperative mortality in hip fracture patients treated with cemented and uncemented hemiprosthesis: a register study of 11,210 patients
    Ove Talsnes
    Department of Orthopaedics, Innlandet Hospital Trust, Elverum, Norway
    Int Orthop 37:1135-40. 2013
    ..Due to inconclusive results in studies of hip fracture patients treated with cemented and uncemented hemiprostheses, this study was initiated...
  23. ncbi request reprint Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin)
    O E Dahl
    Department of Orthopaedics, Ullevaal University Hospital, Oslo, Norway
    Thromb Haemost 77:26-31. 1997
    ..This study shows that prolonged thromboprophylaxis with dalteparin. 5000 IU, once daily for 35 days significantly reduces the frequency of DVT and should be recommended for 5 weeks after hip replacement surgery...
  24. ncbi request reprint Thromboprophylaxis in hip arthroplasty. New frontiers and future strategy
    O E Dahl
    Department of Orthopaedics, Ullevaal University Hospital, Oslo, Norway
    Acta Orthop Scand 69:339-42. 1998
    ..Prolonged thrombo-prophylaxis with low-molecular-weight heparin (dalteparin or enoxaparin) is recommended for at least 5 weeks after the operation...
  25. pmc Clinical and biochemical prediction of early fatal outcome following hip fracture in the elderly
    Ove Talsnes
    Department of Orthopaedics, Elverum Central Hospital, Elverum, Norway
    Int Orthop 35:903-7. 2011
    ....
  26. ncbi request reprint Cardiorespiratory and vascular dysfunction related to major reconstructive orthopedic surgery
    O E Dahl
    Department of Orthopaedics, Ullevaal University Hospital, Oslo, Norway
    Acta Orthop Scand 68:607-14. 1997
    ..All these effects may finally induce hemodynamic insufficiency, which occasionally may be fatal. To prevent these adverse reactions, thrombin activity should be reduced and impaction of bone cement minimized...
  27. ncbi request reprint Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies
    William D Fisher
    McGill University Health Centre, 1650 Cedar Avenue, Montreal, Quebec, H3G 1A4, Canada
    Thromb Haemost 97:931-7. 2007
    ..Overall, rivaroxaban total daily doses of 5-20 mg had the most favorable balance of efficacy and safety, relative to enoxaparin, for the prevention of VTE after major orthopaedic surgery...
  28. ncbi request reprint Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial
    Bengt I Eriksson
    Department of Orthopaedic Surgery, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    Lancet 360:1441-7. 2002
    ..We aimed to compare the efficacy and safety with that of dalteparin...
  29. ncbi request reprint Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement
    Bengt I Eriksson
    Orthopaedics Department, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    Thromb Haemost 89:288-96. 2003
    ..0%) and 306/1122 (27.3%) patients in the ximelagatran and enoxaparin group, respectively, a difference in risk of 3.7% in favour of enoxaparin (p = 0.053). Bleeding was comparable between the two groups...
  30. ncbi request reprint Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool
    Meyer Michel Samama
    Service d Hematologie Biologique, Hopital Hotel Dieu, 1, place Parvis Notre Dame, F 75181 Paris, Cedex 04, France
    Haematologica 88:1410-21. 2003
    ..As the first step in creating a tool to assess an individual patient's risk of venous thromboembolism, we carried out a literature review in order to quantify risk factors for venous thromboembolism...
  31. ncbi request reprint Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors
    Bengt I Eriksson
    Department of Orthopaedic Surgery, Sahlgrenska University Hospital Ostra, SE 416 85 Goteborg, Sweden
    Drugs 64:577-95. 2004
    ..Ximelagatran can be used with an oral fixed dose without the need for coagulation monitoring or dose adjustment. Hence, it offers significant potential to facilitate the management of anticoagulation in or out of hospital...
  32. ncbi request reprint An electronic tool for venous thromboembolism prevention in medical and surgical patients
    Meyer Michel Samama
    Hotel Dieu, Paris, France
    Haematologica 91:64-70. 2006
    ..Because appropriate prevention with thromboprophylaxis is underused, we wanted to create an electronic tool to provide a simple risk assessment and suggest appropriate prophylaxis...
  33. ncbi request reprint A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement
    Bengt I Eriksson
    Department of Orthopaedics, Sahlgrenska University Hospital Ostra, SE 416 85 Gothenburg, Sweden
    Circulation 114:2374-81. 2006
    ..Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--could be an alternative to heparins and warfarin for the prevention and treatment of thromboembolic disorders...
  34. ncbi request reprint Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement
    Wolfgang Mueck
    Bayer HealthCare AG, Aprather Weg 18a, Wuppertal, Germany
    Thromb Haemost 100:453-61. 2008
    ....
  35. ncbi request reprint Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery
    Wolfgang Mueck
    Clinical Pharmacology, Bayer HealthCare AG, Aprather Weg 18a, Wuppertal, Germany
    Clin Pharmacokinet 47:203-16. 2008
    ....
  36. ncbi request reprint Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement
    Bengt I Eriksson
    Department of Orthopaedics, Sahlgrenska University Hospital Ostra, SU Ostra sjukhuset, SE 41685 Goteborg, Sweden
    Thromb Res 120:685-93. 2007
    ..Rivaroxaban (BAY 59-7939) is a novel, oral, direct Factor Xa inhibitor in clinical development for the prevention of thromboembolic disorders. The aim of this study was to demonstrate proof-of-principle for rivaroxaban...